about
High throughput quantitative reverse transcription PCR assays revealing over-expression of cancer testis antigen genes in multiple myeloma stem cell-like side population cells.Correlation between CD117+ myeloma plasma cells and hematopoietic progenitor cells in different categories of patientsPanobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level Data.Autopsy Analysis may Contribute to Establish Actual Incidence of Second Primary Malignancies in Myeloma.The inflammatory chemokine CCL5 and cancer progressionMiRNA-34a overexpression inhibits multiple myeloma cancer stem cell growth in mice by suppressing TGIF2.The role of P-glycoprotein in drug resistance in multiple myeloma.Novel agents and new therapeutic approaches for treatment of multiple myeloma.Brain Abscesses Caused by Nocardia paucivorans in a Multiple Myeloma Patient Treated with Lenalidomide and Dexamethasone: a Case Report and Review of Literature.Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.PEGylated long-circulating liposomes deliver homoharringtonine to suppress multiple myeloma cancer stem cellsInhibitory effect of epirubicin-loaded lipid microbubbles with conjugated anti-ABCG2 antibody combined with therapeutic ultrasound on multiple myeloma cancer stem cells.Th22 cells increase in poor prognosis multiple myeloma and promote tumor cell growth and survival.Sequential Exposure of Bortezomib and Vorinostat is Synergistic in Multiple Myeloma Cells.AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia.Mechanisms of Resistance in Multiple Myeloma.Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against.Cell Signaling Model Connects Vorinostat Pharmacokinetics and Tumor Growth Response in Multiple Myeloma Xenografts.A historical perspective on milestones in multiple myeloma research.The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5.
P2860
Q35194860-0FFFF75E-B66A-49E5-9DAF-373C831D57F3Q35765157-E2EA90EF-CAD4-4029-8299-26BDC85AEAF6Q36109802-059AD292-8262-4E5F-BD96-9EE6B1937E42Q36438206-E9E17330-D3B8-4C1F-B010-A0691C6D4F65Q37541911-C5430A2B-BD86-4759-9BF7-9D0106DEE9ABQ37553776-029710B2-D1C2-48BD-A513-86EB194B9242Q38200143-95A31DB7-12E3-4ACF-851D-458FD9EFDBFEQ38261677-179B1BD8-8769-4CF9-A5DB-C088922BD8C4Q38312608-8CBAF2D5-F6B5-4F4E-B436-4E913F82673BQ38662385-3BDC7500-4C27-4682-924C-A5413EA00DC8Q38722800-808D3243-5E1E-4BFF-B8CB-22E0299D84EDQ38850040-F8399988-357D-4AD5-BDBE-293A8E7E2573Q38855371-B64AD58E-C669-4493-981E-2E75C8CD4338Q39013265-21EE4DF0-8F63-48A6-A5AD-6D3F6FCEE258Q39062888-5150417A-235D-43DE-A90C-C584B8C07692Q39185604-7E966699-0286-4058-90F8-9610195B8025Q47230178-FAFAC858-3BD7-45AA-9D81-A4EB9DFD4122Q47418005-2221D25A-2170-4804-9726-839C82BF5A42Q47633998-73475B17-62EA-47D5-BBDB-0C142AE43B34Q48196787-84EC9FBF-62DF-4FDC-B266-A9DC450978DFQ53543459-290FAECD-E167-4496-B221-A36961161470
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Can we change the disease biology of multiple myeloma?
@en
type
label
Can we change the disease biology of multiple myeloma?
@en
prefLabel
Can we change the disease biology of multiple myeloma?
@en
P2860
P1433
P1476
Can we change the disease biology of multiple myeloma?
@en
P2093
Ivan Borrello
P2860
P356
10.1016/S0145-2126(12)70003-6
P478
36 Suppl 1
P577
2012-11-01T00:00:00Z